New combo shot aims to simplify type 2 diabetes management

NCT ID NCT06716424

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a fixed-dose combination of insulin glargine and lixisenatide (iGlarLixi) in 105 adults with type 2 diabetes whose blood sugar is not well controlled on oral drugs or other injectables. The main goal is to check safety and side effects, while also measuring changes in blood sugar levels over time. All participants receive the same treatment, so there is no placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: insulin glargine/lixisenatide (iGlarLixi)
What this could lead to: If successful, this could offer a convenient single-injection option to help people with type 2 diabetes better control their blood sugar.
What could go wrong: This is a single-arm, phase 4 study with no comparison group, so results may be less definitive. Side effects like low blood sugar or gastrointestinal issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Investigational Site Number : 3560001

Kolkata, 700020, India
Investigational Site Number : 3560003

Kanpur, 208002, India
Investigational Site Number : 3560005

Hyderabad, 500034, India
Investigational Site Number : 3560006

Indore, 452010, India
Investigational Site Number : 3560007

Delhi, 110088, India
Investigational Site Number : 3560008

Pune, 411004, India
Investigational Site Number : 3560009

Bengaluru, 560054, India
Investigational Site Number : 3560011

Jaipur, 302020, India
Investigational Site Number : 3560014

Visakhapatnam, 530040, India
Investigational Site Number: 3560013

Pune, 411057, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.